GRIbio is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of inflammatory, fibrotic, and autoimmune diseases. By advancing innovative therapies, GRIbio aims to fundamentally change the way these conditions are managed. At the heart of GRIbio's approach is the targeting of NKT cells, which are crucial regulators in the inflammatory cascade.

These innate-like T cells bridge the gap between the innate and adaptive immune responses, playing a vital role in disease progression. GRIbio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a groundbreaking oral therapeutic for idiopathic pulmonary fibrosis, a serious condition with limited treatment options. In addition to their flagship program, GRIbio is developing a pipeline of innovative type 2 NKT agonists for the treatment of systemic lupus erythematosus.

With over 500 proprietary compounds at their disposal, GRIbio is well-positioned to drive further advancements in the field. Headquartered in La Jolla, California, GRIbio is committed to advancing new therapies and transforming the lives of patients